Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Cytarabine Generic Name & Formulations
Legal Class
Rx
General Description
Cytarabine 100mg, 500mg, 1g, 2g; per vial; lyophilized pwd for IV, intrathecal, SC inj after reconstitution.
Pharmacological Class
Antimetabolite.
How Supplied
Vials (100mg, 200mg)—10
1g, 2g—1
1g, 2g—1
Manufacturer
Cytarabine Indications
Indications
Remission induction in acute non-lymphocytic leukemia of adults and children. Acute lymphocytic leukemia. Chronic myelocytic leukemia (blast phase). Prophylaxis and treatment of meningeal leukemia (intrathecal route).
Cytarabine Dosage and Administration
Adults and Children
Induction therapy of acute non-lymphocytic leukemia: 100mg/m2 per day by continuous IV infusion (days 1–7) or 100mg/m2 IV every 12 hours (days 1–7). Acute lymphocytic leukemia and chronic myelocytic leukemia: see literature. Meningeal leukemia: Usual range: 5–75mg/m2 intrathecally; may give once daily for 4 days to once every 4 days; most frequently used dose: 30mg/m2 every 4 days until cerebrospinal fluid findings are normal.
Cytarabine Contraindications
Not Applicable
Cytarabine Boxed Warnings
Not Applicable
Cytarabine Warnings/Precautions
Warnings/Precautions
Do not use diluent with benzyl alcohol for intrathecal administration. Pre-existing myelosuppression. Renal or hepatic impairment. Monitor blood counts, renal, hepatic function. Neonates. Pregnancy (Cat.D); avoid use. Nursing mothers.
Cytarabine Pharmacokinetics
See Literature
Cytarabine Interactions
Interactions
May antagonize gentamicin, fluorocytosine.
Cytarabine Adverse Reactions
Adverse Reactions
Myelosuppression (leukopenia, thrombocytopenia, anemia), GI upset, anorexia, abdominal pain, oral ulceration, rash, fever, hepatic dysfunction, infection, bleeding; cytarabine syndrome, hyperuricemia, pancreatitis, paralysis (rare), others.
Cytarabine Clinical Trials
See Literature
Cytarabine Note
Not Applicable
Cytarabine Patient Counseling
See Literature
